Efficacy of therapies following venetoclax discontinuation in CLL: Focus on B-cell receptor signal transduction inhibitors and cellular therapies Meeting Abstract


Authors: Mato, A. R.; Roeker, L. E.; Eyre, T. A.; Jacobs, R.; Hill, B. T.; Lamanna, N.; Brander, D. M.; Shadman, M.; Ujjani, C.; Yazdy, M.; Perini, G. F.; Ibarz, J. P.; Barrientos, J. C.; Skarbnik, A.; Torka, P.; Pu, J. J.; Pagel, J. M.; Gohil, S.; Fakhri, B.; Choi, M. Y.; Coombs, C. C.; Rhodes, J.; Barr, P. M.; Portell, C. A.; Parry, H.; Garcia, C. A.; Whitaker, K. J.; Winter, A. M.; Sitlinger, A.; Khajavian, S.; Grajales-Cruz, A. F.; Isaac, K.; Shah, P.; Akhtar, O. S.; Pocock, R.; Lam, K.; Voorhees, T. J.; Schuster, S. J.; Rodgers, T. D.; Martinez-Calle, N.; Munir, T.; Bhavsar, E. B.; Bailey, N.; Lee, J. C.; Weissbrot, H.; Nabhan, C.; Goodfriend, J.; King, A. C.; Zelenetz, A. D.; Dorsey, C.; Bigelow, K.; Cheson, B. D.; Fox, C. P.; Allan, J. N.
Abstract Title: Efficacy of therapies following venetoclax discontinuation in CLL: Focus on B-cell receptor signal transduction inhibitors and cellular therapies
Meeting Title: 61st Annual Meeting and Exposition of the American Society of Hematology (ASH)
Journal Title: Blood
Volume: 134
Issue: Suppl. 1
Meeting Dates: 2019 Dec 7-10
Meeting Location: Orlando, FL
ISSN: 0006-4971
Publisher: American Society of Hematology  
Date Published: 2019-11-13
Language: English
ACCESSION: WOS:000518218500341
DOI: 10.1182/blood-2019-123747
PROVIDER: wos
Notes: Meeting Abstract: 502 -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Andrew D Zelenetz
    767 Zelenetz
  2. Amber Courtney King
    32 King
  3. Anthony R Mato
    235 Mato
  4. Lindsey Elizabeth Roeker
    132 Roeker
  5. Colleen Dorsey
    16 Dorsey
Related MSK Work